Navigation Links
Echo Therapeutics to Present at Jessup & Lamont 2009 Growth Stock Conference
Date:7/20/2009

FRANKLIN, Mass., July 20 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will present at the Jessup & Lamont 2009 Growth Stock Conference organized by the LifeTech Capital Group on Thursday, July 30, 2009 at 1:15 pm ET. The presentation will occur live and will be held at The Boca Raton Resort & Club in Boca Raton, Florida.

"We look forward to presenting Symphony, our needle-free, continuous glucose monitoring technology, and Prelude our needle-free skin preparation for transdermal drug delivery to the large audience of industry leaders, institutional and retail investors from around the world who will be attending the conference. We also plan to provide an update on our notable progress toward our goal of making Symphony and Prelude available to physicians and patients in early 2010," stated Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.

About Echo Therapeutics

Echo Therapeutics is focused on medical devices and specialty pharmaceuticals. Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude(TM) SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the efficacy of Echo's Symphony tCGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM System, the ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic products based on its skin permeation platform technologies, including the Symphony tCGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:

    Patrick T. Mooney, M.D.
    Chairman and Chief Executive Officer
    (508)-530-0329


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... June 25, 2017 , ... June is Men’s Health Month and the focus ... cancer among men in the U.S. and the third most common cause of cancer related ... one man in seven will be diagnosed with prostate cancer during his lifetime. Those ...
(Date:6/24/2017)... ... June 24, 2017 , ... The Pennsylvania Athletic Trainers’ Society’s ... and Erie Convention Center on June 8-10. The weekend consisted of many ... award and scholarship presentations, and professional networking. , On Friday June 9th, ...
(Date:6/24/2017)... (PRWEB) , ... June 24, 2017 , ... The weather ... spend time outdoors. Home and business owners should be aware that the summer months ... lake. In fact, mechanical locks and keys can be negatively affected from direct exposure ...
(Date:6/23/2017)... Providence, RI (PRWEB) , ... June 23, 2017 ... ... Community Care Network today announced the launch of Care Management Alerts and Dashboards, ... for 140,000 patients throughout Rhode Island. , RIQI’s Care Management Alerts and Dashboards ...
(Date:6/23/2017)... ... June 23, 2017 , ... By scoring 100% for fiscal management and accountability, ... premier online charity evaluator, Charity Navigator, validating ANRF's work as a top charity in ... by Charity Navigator and earns ANRF a spot on their “ 10 Charities Worth ...
Breaking Medicine News(10 mins):
(Date:6/20/2017)... Inc. (NYSE: HRC), will host its fiscal third quarter 2017 ... beginning at 7:30 a.m. (CDT) / 8:30 a.m. (EDT). ... the conference call, dial (877) 304-8969 (domestic) or (631) 291-4543 ... prior to the start to allow time to connect. The ... Webcast: A simultaneous webcast of the call will be ...
(Date:6/16/2017)... 16, 2017 Datascope Corp. is voluntarily performing a worldwide field ... potential electrical test failure code.     ... PART NUMBER ... IABP 0998-UC-0446HXX; 0998-UC-0479HXX ... This field correction also ...
(Date:6/14/2017)... Va. , June 14, 2017  ivWatch LLC, ... and effectiveness of intravenous (IV) therapy, is pleased to ... the category of Nonsurgical Hospital Supplies and Equipment at ... awards program for the medtech industry. The award was ... the Jacob K. Javits Center in New ...
Breaking Medicine Technology: